Other β-lactam. A. Carbapenems:

Size: px
Start display at page:

Download "Other β-lactam. A. Carbapenems:"

Transcription

1 A. Carbapenems: Other β-lactam Carbapenems are synthetic β-lactam antibiotics Differ in structure from the penicillins in that the sulfur atom of the thiazolidine ring. Imipenem, meropenem, doripenem, and ertapenem are the drugs of this group currently available. Imipenem is compounded with cilastatin to protect it from metabolism by renal dehydropeptidase.

2 Antibacterial Spectrum: Imipenem resists hydrolysis by most β- lactamases. This drug plays a role in empiric therapy because it is active against β-lactamase producing gram-positive and gramnegative organisms, anaerobes, and P. aeruginosa.

3

4 Pharmacokinetics: Imipenem/cilastatin and meropenem are administered IV Excreted by glomerular filtration. Imipenem undergoes cleavage by a dehydropeptidase found in the brush border of the proximal renal tubule. Inactive metabolite is resulted that is potentially nephrotoxic. Compounding the imipenem with cilastatin protects the parent drug and, thus, prevents the formation of the toxic metabolite. The other carbapenems do not require coadministration of cilastatin.

5 Monobactams β-lactam ring is not fused to another ring Aztreonam which is the only commercially available monobactam has antimicrobial activity Directed primarily against gram-negative pathogens. It lacks activity against gram positive organisms and anaerobes. Aztreonam is resistant to the action of most β-lactamases. Administered either IV or IM. Aztreonam is relatively nontoxic. it shows little cross-reactivity with antibodies induced by other β-lactams. May offer a safe alternative for treating patients who are allergic to other penicillins cephalosporins, or carbapenems.

6 Monobactams

7 β-lactamase Inhibitors Hydrolysis of the β-lactam ring.destroys the antimicrobial activity of a β-lactam antibiotic. β-lactamase inhibitors: Clavulanic Acid Sulbactam Tazobactam o Contain a β-lactam ring but, by themselves, do not have significant antibacterial activity or cause any significant adverse effects. o Bind to and inactivate β-lactamases, thereby protecting the antibiotics that are normally substrates for these enzymes. o The β-lactamase inhibitors are therefore formulated in combination with β-lactamase sensitive.

8

9

10 Vancomycin Vancomycin has become increasingly important in the treatment of lifethreatening infections. MRSA infections. Methicillin-resistant Staphylococcus epidermidis (MRSE) infections Enterococcal infections.

11 Daptomycin Telavancin Fosfomycin Polymyxins

12 Protein Synthesis Inhibitors

13 Protein Synthesis Inhibitors o Antibiotics exert their antimicrobial effects by targeting bacterial ribosomes and inhibiting bacterial protein synthesis. o Bacterial ribosomes composed of 30S and 50S subunits. o Mammalian ribosomes have 40S and 60S subunits. o Selectivity minimizes potential adverse o Structure of mitochondrial ribosomes more closely resembles bacterial ribosomes. High concentration side effect(tetracyclines and chloramphenicol).

14 Mechanism of action: Tetracyclines

15

16 Absorption Administration with dairy products or other substances that contain divalent and trivalent cations (magnesium, aluminum antacids or iron supplements) decreases absorption particularly for tetracycline.

17 Tetracyclines Bacteriostatic including gram-positive and gram-negative bacteria. Resistance to tetracyclines is: Efflux pump that expels drug out of the cell Enzymatic inactivation of the drug. Production of bacterial proteins that prevent tetracyclines from binding to the ribosome.

18 Contraindications: The tetracyclines should not be used in pregnant. Breast-feeding women. Children less than 8 years of age.

19

life-threatening infections

life-threatening infections Vancomycin Vancomycin has become increasingly important in the treatment of life-threatening infections. MRSA infections. Methicillin-resistant Staphylococcus epidermidis (MRSE) infections Enterococcal

More information

Development of C sporins. Beta-lactam antibiotics - Cephalosporins. Second generation C sporins. Targets - PBP s

Development of C sporins. Beta-lactam antibiotics - Cephalosporins. Second generation C sporins. Targets - PBP s Beta-lactam antibiotics - Cephalosporins Development of C sporins Targets - PBP s Activity - Cidal - growing organisms (like the penicillins) Principles of action - Affinity for PBP s Permeability properties

More information

Anti-Microbial Drugs

Anti-Microbial Drugs Name: Date: Monday March 7 th 2011 Class: I "Pharmacology Anti-Microbial Drugs Lecture 5 د. حيدر الشكرجي Macrolides: Anti-Microbial Drugs Erythromycin was the 1 st of macrolides to find clinical application,

More information

Use of imipenem. with the support of Wallonie-Bruxelles International. Magali Dodémont Microbiology Hospital Erasme Université Libre de Bruxelles

Use of imipenem. with the support of Wallonie-Bruxelles International. Magali Dodémont Microbiology Hospital Erasme Université Libre de Bruxelles with the support of Wallonie-Bruxelles International Use of imipenem Magali Dodémont Microbiology Hospital Erasme Université Libre de Bruxelles 1 Β-lactams classification 2 Β-lactams: mode of action Inhibition

More information

Microbiology - Problem Drill 16: Antibiotics. Question No. 1 of 10. Question. Feedback. Question

Microbiology - Problem Drill 16: Antibiotics. Question No. 1 of 10. Question. Feedback. Question Microbiology - Problem Drill 16: Antibiotics No. 1 of 10 1. An effective chemotherapeutic drug should have. (A) Low therapeutic index (B) More toxicity (C) Selective toxicity (D) Mutation inducing properties

More information

Protein Synthesis Inhibitors. Ass Prof. Dr. Naza M. Ali 15 Nov 2018 Lec 8

Protein Synthesis Inhibitors. Ass Prof. Dr. Naza M. Ali 15 Nov 2018 Lec 8 Protein Synthesis Inhibitors Ass Prof. Dr. Naza M. Ali 15 Nov 2018 Lec 8 These drugs selectively inhibit bacterial protein synthesis. The selectivity is due to the differences between bacterial and human

More information

Vancomycin. A bactericidal drug which acts by inhibiting cell wall synthesis. Active only against gram-positive bacteria, particularly staphylococci.

Vancomycin. A bactericidal drug which acts by inhibiting cell wall synthesis. Active only against gram-positive bacteria, particularly staphylococci. Vancomycin A bactericidal drug which acts by inhibiting cell wall synthesis. Active only against gram-positive bacteria, particularly staphylococci. Used IV in treating endocarditis caused by methicillin-resistant

More information

AXITAB-CV TAB. COMPOSITION :

AXITAB-CV TAB. COMPOSITION : AXITAB-CV TAB. COMPOSITION : Each film coated tablet contains: Cefuroxime Axetil I.P. Eq. to Anhydrous 500mg. Potassium Clavulanate Diluted I.P. Eq. to Clavulanic Acid 125mg DESCRIPTION : Cefuroxime Axetil

More information

MCQ S. 1. Which of the following could be given to someone who had an allergy to sulphonamides previously:

MCQ S. 1. Which of the following could be given to someone who had an allergy to sulphonamides previously: MCQ S 1. Which of the following could be given to someone who had an allergy to sulphonamides previously: a) Acetazolamide b) Frusemide c) Bumetanide d) Pyrimethamine e) Diazoxide 2. Which of the following

More information

Affinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED

Affinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED AAC Accepts, published online ahead of print on February 00 Antimicrob. Agents Chemother. doi:./aac.01-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights

More information

Rapid identification and resistance assessment: The future is mass spectrometry

Rapid identification and resistance assessment: The future is mass spectrometry Rapid identification and resistance assessment: The future is mass spectrometry Dr Sanmarié Schlebusch Director of Microbiology Mater Pathology Brisbane Outline Introduction Plug and play Pre-prep and

More information

Overcoming the PosESBLities of Enterobacteriaceae Resistance

Overcoming the PosESBLities of Enterobacteriaceae Resistance Overcoming the PosESBLities of Enterobacteriaceae Resistance Review of current treatment options Jamie Reed, PharmD Pharmacy Grand Rounds August 28, 2018 Rochester, MN 2018 MFMER slide-1 Disclosure No

More information

THE NON PENICILLIN BETA LACTAM DRUG CROSS CONTAMINATION PREVENTION; USFDA PERSPECTIVE

THE NON PENICILLIN BETA LACTAM DRUG CROSS CONTAMINATION PREVENTION; USFDA PERSPECTIVE THE NON PENICILLIN BETA LACTAM DRUG CROSS CONTAMINATION PREVENTION; USFDA PERSPECTIVE An overview by Sarah Vugigi, M. Pharm, Elys Chemical Industries Ltd, Nairobi, Kenya INTRODUCTION This guidance describes

More information

number Done by Corrected by Doctor مالك الزحلف

number Done by Corrected by Doctor مالك الزحلف number 30 Done by حسام أبو عوض Corrected by Shahd Alqudah Doctor مالك الزحلف Vancomycin As mentioned in the previous lecture, vancomycin is a pure gram-positive drug (has no effect on gram-negative bacteria),

More information

STRUCTURE OF COMMONLY USED PENICILLINS

STRUCTURE OF COMMONLY USED PENICILLINS PENICILLINS Alice Prince I. CHEMISTRY A basic structure of penicillins consists of a nucleus with three components: a thiazolidine ring, a β-lactam ring and a side chain. The side chain determines, in

More information

Aminoglycosides. Not orally absorbed. Interact with negatively charged lipopolysaccharide on Gram- cell wall. Aminoglycoside properties

Aminoglycosides. Not orally absorbed. Interact with negatively charged lipopolysaccharide on Gram- cell wall. Aminoglycoside properties Aminoglycosides Tobramycin Kanamycin H2N Gentamicin Amikacin NHCOCHCH2CH2NH2 OH Aminoglycosides made of linked sugars. Decorated with many OH and NH2 groups, which render these compounds positively charged

More information

Protein Synthesis Inhibitors

Protein Synthesis Inhibitors Frank Lowy Protein Synthesis Inhibitors This lecture discusses a diverse group of antibiotics that are grouped together because they all have a common mechanism of action they are protein synthesis inhibitors.

More information

Laboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator

Laboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator Nebraska Public Health Laboratory 2008 CLSI M100-S18 update Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator Agenda Discuss 2008 M100- S18

More information

Urinary Tract Infections: From Simple to Complex. Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014

Urinary Tract Infections: From Simple to Complex. Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014 Urinary Tract Infections: From Simple to Complex Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014 Learning Objectives Develop empiric antimicrobial treatment

More information

Discussion points CLSI M100 S19 Update. #1 format of tables has changed. #2 non susceptible category

Discussion points CLSI M100 S19 Update. #1 format of tables has changed. #2 non susceptible category Discussion points 2009 CLSI M100 S19 Update Nebraska Public Health Laboratory Changes most important to routine antimicrobial susceptibility testing. Documents available Janet Hindler discussion slide

More information

Annual Surveillance Summary: Pseudomonas aeruginosa Infections in the Military Health System (MHS), 2016

Annual Surveillance Summary: Pseudomonas aeruginosa Infections in the Military Health System (MHS), 2016 Annual Surveillance Summary: Pseudomonas aeruginosa Infections in the Military Health System (MHS), 2016 Sarah Gierhart and Uzo Chukwuma Approved for public release. Distribution is unlimited. The views

More information

Continuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook

Continuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook Continuous Infusion of Antibiotics In The ICU: What Is Proven? Michael S. Niederman, M.D. Chairman, Department of Medicine Winthrop-University Hospital Mineola, NY Professor of Medicine Vice-Chairman,

More information

Macrolides, Clindamycin & Ketolides Polymyxins

Macrolides, Clindamycin & Ketolides Polymyxins Macrolides, Clindamycin & Ketolides Polymyxins Kwan Soo Ko Macrolides - Erythromycin - Azithromycin - Clarithromycin Lincosamides - Lincomycin - Clindamycin Unrelated chemically But, many similar biological

More information

Adenium Biotech. Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes

Adenium Biotech. Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes Adenium Biotech Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes Board of Directors: - Stephan Christgau, PhD, chairman,

More information

Antibiotics and Ribosomes as Drug Targets

Antibiotics and Ribosomes as Drug Targets Antibiotics and Ribosomes as Drug Targets www.biochemj.org/bj/330/0581/bj3300581.htm Professor Vassie Ware Bioscience in the 21 st Century November 5, 2012 PERSPECTIVE Widespread use of antibiotics after

More information

Shirin Abadi, B.Sc.(Pharm.), ACPR, Pharm.D. Clinical Pharmacy Specialist & Pharmacy Education Coordinator, BC Cancer Agency Clinical Associate

Shirin Abadi, B.Sc.(Pharm.), ACPR, Pharm.D. Clinical Pharmacy Specialist & Pharmacy Education Coordinator, BC Cancer Agency Clinical Associate Shirin Abadi, B.Sc.(Pharm.), ACPR, Pharm.D. Clinical Pharmacy Specialist & Pharmacy Education Coordinator, BC Cancer Agency Clinical Associate Professor of Pharmacy & Associate Member of Medicine, UBC

More information

Translocation Studies Mid-Term Review (MTR) Meeting Marseille, France

Translocation Studies Mid-Term Review (MTR) Meeting Marseille, France Marie Curie Actions Research Training Networks (RTN) Translocation Studies Mid-Term Review (MTR) Meeting Marseille, France F. Vidal-Aroca, M.G.P. Page and J. Dreier Background Deteriorating situation regarding

More information

I is a cascading prodrug. II is used to treat hepatitis B infection III ultimately inhibits viral reverse transcriptase.

I is a cascading prodrug. II is used to treat hepatitis B infection III ultimately inhibits viral reverse transcriptase. Medicinal Chemistry 410 Exam #1 February 19, 2010 ame: Med. Chem. # 1 Part. (75 Points) There are 50 multiple choice questions worth 1.5 points each (75 Points). Please use the cantron heet provided. f

More information

Topical antimicrobial agents in wound care. Professor Val Edwards-Jones Manchester Metropolitan University UK

Topical antimicrobial agents in wound care. Professor Val Edwards-Jones Manchester Metropolitan University UK Topical antimicrobial agents in wound care Professor Val Edwards-Jones Manchester Metropolitan University UK Antimicrobial agents Antibacterial agents Antifungal agents Antiviral agents Antiparasitic agents?others

More information

Penicillin Allergy and Use of Other Antibiotics

Penicillin Allergy and Use of Other Antibiotics Penicillin Allergy and Use of Other Antibiotics 7300-646PT Policy No.: 7310-646PT 8790-646PT Original Policy Date: 10/10/2016 Revision Date(s): Review Date(s): Approval: 11/17/16 Pharmacy & Therapeutics

More information

β- Lactamase Gene carrying Klebsiella pneumoniae and its Clinical Implication

β- Lactamase Gene carrying Klebsiella pneumoniae and its Clinical Implication Prevalence of Carbapenem-Hydrolyzing β- Lactamase Gene carrying Klebsiella pneumoniae and its Clinical Implication David Alcid M.D Balaji Yegneswaran M.D. Wanpen Numsuwan Introduction Klebsiella pneumoniae

More information

Therapeutic drug monitoring of β-lactams

Therapeutic drug monitoring of β-lactams CORATA Belgique Reims 1-2/10/2014 Therapeutic drug monitoring of β-lactams Frédéric Cotton Clinical Chemistry Erasme Hospital Faculty of Pharmacy ULB TDM of β-lactams β-lactams pharmacokinetics pharmacodynamics

More information

Disclosure. Objectives. Evolution of β Lactamases. Extended Spectrum β Lactamases: The New Normal. Prevalence of ESBL Mystic Program

Disclosure. Objectives. Evolution of β Lactamases. Extended Spectrum β Lactamases: The New Normal. Prevalence of ESBL Mystic Program 47 th Annual Meeting August 2-4, 2013 Orlando, FL Extended Spectrum β Lactamases: The New Normal Disclosure I do have a vested interest in or affiliation with the following companies or organizations Triax

More information

Antibiotic Classification Antibiotic Classification and Modes of Action

Antibiotic Classification Antibiotic Classification and Modes of Action and Modes of Action Part # 60-00415-0 1 biomérieux, the blue logo and VITEK are used, pending and/or registered trademarks belonging to biomérieux SA or one of its subsidiaries. CLSI is a registered trademark

More information

Orchestrated Efforts to Optimize Antibiotic Prescriptions in a Medical Department

Orchestrated Efforts to Optimize Antibiotic Prescriptions in a Medical Department Orchestrated Efforts to Optimize Antibiotic Prescriptions in a Medical Department Dr. Eugene Tso Division of Infectious Diseases Department of Medicine & Geriatrics United Christian Hospital 11 May 2010

More information

TRANSPARENCY COMMITTEE. Opinion. 07 January 2009

TRANSPARENCY COMMITTEE. Opinion. 07 January 2009 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 07 January 2009 500 mg, powder for solution for perfusion B/10 bottles (CIP: 387 355-6) Applicant: JANSSEN-CILAG doripenem

More information

Antibiotics to treat multi-drug-resistant bacterial infections

Antibiotics to treat multi-drug-resistant bacterial infections Antibiotics to treat multi-drug-resistant bacterial infections July 2013 JUNE 2013 Copyright 2013 Tetraphase Pharmaceuticals, Inc. 1 Forward Looking Statements and Other Important Cautions Any statements

More information

UPDATES IN ANTIBIOTIC THERAPY OF BILIARY TRACT INFECTIONS

UPDATES IN ANTIBIOTIC THERAPY OF BILIARY TRACT INFECTIONS 6 ARTICOLE ORIGINALE UPDATES IN ANTIBIOTIC THERAPY OF BILIARY TRACT INFECTIONS Cristian Balahura 1,2, Petre Iacob Calistru 1,3, Gabriel Constantinescu 1,2 1 Carol Davila University of Medicine and Pharmacy,

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT HYPERSOL 500 mg/g Powder for use in Drinking water 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 g of product contains: Active

More information

Summary of the risk management plan (RMP) for Zerbaxa (ceftolozane / tazobactam)

Summary of the risk management plan (RMP) for Zerbaxa (ceftolozane / tazobactam) EMA/513109/2015 Summary of the risk management plan (RMP) for Zerbaxa (ceftolozane / tazobactam) This is a summary of the risk management plan (RMP) for Zerbaxa, which details the measures to be taken

More information

Nightmare Bacteria. Disclosures. Technician Objectives. Pharmacist Objectives. Carbapenem Resistance in Carbapenem Resistance in 2017

Nightmare Bacteria. Disclosures. Technician Objectives. Pharmacist Objectives. Carbapenem Resistance in Carbapenem Resistance in 2017 Nightmare Bacteria How to Deal with the Reality of Carbapenem-resistant Organisms Disclosures I have no conflicts of interest relative to the content of this presentation Matthew L. Brown, Pharm.D., BCPS

More information

Plazomicin for complicated urinary tract infection

Plazomicin for complicated urinary tract infection October 2016 Horizon Scanning Research & Intelligence Centre Plazomicin for complicated urinary tract infection NIHR HSRIC ID: 9787 Lay summary Serious infections caused by Gram-negative bacteria are becoming

More information

Paul M. Tulkens Françoise Van Bambeke. Unité de pharmacologie cellulaire et moléculaire & Louvain Drug Research Institute

Paul M. Tulkens Françoise Van Bambeke. Unité de pharmacologie cellulaire et moléculaire & Louvain Drug Research Institute New antimicrobials Paul M. Tulkens Françoise Van Bambeke Unité de pharmacologie cellulaire et moléculaire & Louvain Drug Research Institute Université catholique de Louvain,, Brussels, Belgium Slides are

More information

College of Pharmacy Advanced Clinical Pharmacology Spring 2013 Semester. Antibiotics PCN. Danita 1 Dee Narciso Pharm D

College of Pharmacy Advanced Clinical Pharmacology Spring 2013 Semester. Antibiotics PCN. Danita 1 Dee Narciso Pharm D College of Pharmacy Advanced Clinical Pharmacology Spring 2013 Semester Antibiotics PCN Danita 1 Dee Narciso Pharm D 2 Objectives Recognize the signs and symptoms of infection Become familiar with antibiotics

More information

Tetracyclines Chloramphenicol Aminoglycosides Macrolides

Tetracyclines Chloramphenicol Aminoglycosides Macrolides Protein synthesis inhibitors Antimicrobial protein synthesis inhibitors Joseph K. Ritter, PhD Assoc. Prof Department of Pharmacology and Toxicology MSB Room 536 jritter@mail2.vcu.edu 828-1022 Tetracyclines

More information

Adult Inpatient Antibiogram. Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates. January to December 2016

Adult Inpatient Antibiogram. Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates. January to December 2016 Adult Inpatient Antibiogram Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates January to December 2016 Department of Pathology Camille Hamula, PhD Director, Clinical Microbiology

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Hospital Universitario Virgen Macarena, Seville New drugs against MRSA and VRE L. Eduardo López Cortés Seville, 8th July Tedizolid Oxazolidinone Ceftaroline // Ceftobiprole 5 th gen cephalosporin Overview

More information

Medicinal Chemistry of Modern Antibiotics

Medicinal Chemistry of Modern Antibiotics Chemistry 259 Medicinal Chemistry of Modern Antibiotics Spring 2012 Lecture 6: Antibiotics Classes & Targets Part I: Drugs Targeting Bacterial Cell Wall & Membrane Thomas Hermann Department of Chemistry

More information

Activity of Ceftolozane/Tazobactam Against a Broad Spectrum of Recent Clinical Anaerobic Isolates

Activity of Ceftolozane/Tazobactam Against a Broad Spectrum of Recent Clinical Anaerobic Isolates AAC Accepts, published online ahead of print on 25 November 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.02253-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. Activity

More information

ROSOBAC-1GM / ROSOBAC-FORT

ROSOBAC-1GM / ROSOBAC-FORT ROSOBAC-1GM / ROSOBAC-FORT ROSOBAC - 1GM. COMPOSITION : Each vial contains Sterile Cefoperazone Sodium IP Eq. to Anhydrous Cefoperazone - Sterile Sulbactam Sodium USP Eq. to Anhydrous Sulbactam - ROSOBAC

More information

Antibiotic Treatment of GNR MDR Infections. Stan Deresinski

Antibiotic Treatment of GNR MDR Infections. Stan Deresinski Antibiotic Treatment of GNR MDR Infections Stan Deresinski Kucers: The Use of Antibiotics 1st Edition 1972 392 pages Kucers: The Use of Antibiotics 7 th Edition 2017 5338 pages Carbapenem Susceptibility

More information

Medicinal Chemistry of Modern Antibiotics

Medicinal Chemistry of Modern Antibiotics Chemistry 259 Medicinal Chemistry of Modern Antibiotics Spring 2008 Lecture 6: Antibiotics Classes & Targets Part I: Drugs Targeting Bacterial Cell Wall & Membrane Thomas Hermann Department of Chemistry

More information

Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections

Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections REVIEW ARTICLE Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections Haley J. Morrill, 1,2 Jason M. Pogue, 3 Keith S. Kaye, 4 and Kerry L. LaPlante 1,2,5 1 Veterans Affairs Medical Center,

More information

Treatment of febrile neutropenia in patients with neoplasia

Treatment of febrile neutropenia in patients with neoplasia Treatment of febrile neutropenia in patients with neoplasia George Samonis MD, PhD Medical Oncologist Infectious Diseases Specialist Professor of Medicine The University of Crete, Heraklion,, Crete, Greece

More information

Summary of Product Characteristics

Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Meroponia 1g Powder for Solution for Injection or Infusion Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains meropenem trihydrate

More information

Antibiotics: Definition CHAPTER 37. Antibiotics. NDEG 26 A Pharmacology I Eliza Rivera-Mitu, RN, MSN. Antibiotics: Classes

Antibiotics: Definition CHAPTER 37. Antibiotics. NDEG 26 A Pharmacology I Eliza Rivera-Mitu, RN, MSN. Antibiotics: Classes CHAPTER 37 Antibiotics NDEG 26 A Pharmacology I Eliza Rivera-Mitu, RN, MSN Antibiotics: Definition Medications used to treat bacterial infections Ideally, before beginning antibiotic therapy, the suspected

More information

Cases in employees. Cases. Day of onset (July)

Cases in employees. Cases. Day of onset (July) Cases in employees 70 60 50 Cases 40 30 20 10 0 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 Day of onset (July) 70 60 50 40 Cases 30 Cases in employees and visitors Employees Visitors 20 10 0 0 2 4 6 8

More information

Acute Cholangitis. Kelsey Knotts PharmD Candidate Class of 2016

Acute Cholangitis. Kelsey Knotts PharmD Candidate Class of 2016 Acute Cholangitis Kelsey Knotts PharmD Candidate Class of 2016 Learning Objectives 1. Describe the mechanism of the development of acute cholangitis 2. Identify common causative organisms in acute cholangitis

More information

Medicinal Chemistry 410 Exam #1 February 20, 2009 Name: Med. Chem. #

Medicinal Chemistry 410 Exam #1 February 20, 2009 Name: Med. Chem. # Medicinal Chemistry 410 Exam #1 February 20, 2009 ame: Med. Chem. # 1 Part. (75 Points) There are 50 multiple choice questions worth 1.5 points each (75 Points). Please use the cantron heet provided. f

More information

Prevalence of Extended Spectrum -Lactamases In E.coli and Klebsiella spp. in a Tertiary Care Hospital

Prevalence of Extended Spectrum -Lactamases In E.coli and Klebsiella spp. in a Tertiary Care Hospital ISSN: 2319-7706 Volume 3 Number 10 (2014) pp. 474-478 http://www.ijcmas.com Original Research Article Prevalence of Extended Spectrum -Lactamases In E.coli and Klebsiella spp. in a Tertiary Care Hospital

More information

Infectious Disease in the Critically Ill Patient

Infectious Disease in the Critically Ill Patient Infectious Disease in the Critically Ill Patient Heather L. Evans, MD MS FACS Director of Surgical Infectious Disease Harborview Medical Center Asst. Professor UW Department of Surgery New Antibiotics:

More information

Guidance for Industry

Guidance for Industry Reprinted from FDA s website by Guidance for Industry Non-Penicillin Beta-Lactam Risk Assessment: A CGMP Framework DRAFT GUIDANCE This guidance document is being distributed for comment purposes only.

More information

gram neg.(semisynthetic) Bacteria Drugs that inhibit cell wall synthesis Drug Action Organisms Comments Spectrum of Action Mycobacterium

gram neg.(semisynthetic) Bacteria Drugs that inhibit cell wall synthesis Drug Action Organisms Comments Spectrum of Action Mycobacterium Mickey Dufilho s Drugs and Bugs Revised 10/10/15 Bacteria Drugs that Inhibit Cell Wall Synthesis Drug Action Spectrum of Action Comments Spectrum of Action Bacitracin Beta-Lactam antibiotics Penicillin

More information

number Done by Corrected by Doctor Hamed Al Zoubi

number Done by Corrected by Doctor Hamed Al Zoubi number 8 Done by م ها أبو عجمي ة Corrected by Mamoon Alqtamin Doctor Hamed Al Zoubi The last page includes definitions for the underlined asterisked words *, You can skip Extra notes, Enjoy! A Brief Introduction

More information

Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria from ICU Patients with Pneumonia

Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria from ICU Patients with Pneumonia Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria from ICU Patients with Pneumonia Helio S. Sader, M.D.* Mariana Castanheira, Ph.D. Rodrigo E. Mendes, Ph.D. Robert K. Flamm, Ph.D. JMI

More information

NONFERMENTING GRAM NEGATIVE RODS. April Abbott Deaconess Health System Evansville, IN

NONFERMENTING GRAM NEGATIVE RODS. April Abbott Deaconess Health System Evansville, IN NONFERMENTING GRAM NEGATIVE RODS April Abbott Deaconess Health System Evansville, IN OBJECTIVES Discuss basic limitations to assessing carbapenem resistance in nonfermenting GNRs Discuss antimicrobial

More information

Beta-Lactam Use in Penicillin Allergic Patients Clinical Guideline

Beta-Lactam Use in Penicillin Allergic Patients Clinical Guideline RECOMMENDATIONS: Beta-Lactam Use in Penicillin Allergic Patients Clinical Guideline 1. Penicillin Anaphylaxis (Type-1 IgE Mediated hypersensitivity) a. May use Cephalosporins and Carbapenems 2. Penicillin

More information

Foot infections are now among the most

Foot infections are now among the most Article Progress in a pedestrian problem: A review of the revised Infectious Diseases Society of America diabetic foot infection guidelines Benjamin A Lipsky This article was first published in The Diabetic

More information

DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES

DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health

More information

PK/PD degli antibiotici utilizzati nella sepsi

PK/PD degli antibiotici utilizzati nella sepsi PK/PD degli antibiotici utilizzati nella sepsi Dario Cattaneo, U.O. Farmacologia Clinica ASST Fatebenefratelli Sacco, Milano Bergamo, città alta Variability of antibiotic concentrations in critically ill

More information

IN VITRO ACTIVITY OF POLYMYXIN B AND MEROPENEM ALONE AND IN COMBINATION AGAINST CARBAPENEM- RESISTANT ENTEROBACTERIACEAE

IN VITRO ACTIVITY OF POLYMYXIN B AND MEROPENEM ALONE AND IN COMBINATION AGAINST CARBAPENEM- RESISTANT ENTEROBACTERIACEAE University of Kentucky UKnowledge Theses and Dissertations--Pharmacy College of Pharmacy 2016 IN VITRO ACTIVITY OF POLYMYXIN B AND MEROPENEM ALONE AND IN COMBINATION AGAINST CARBAPENEM- RESISTANT ENTEROBACTERIACEAE

More information

New Zealand Data Sheet

New Zealand Data Sheet New Zealand Data Sheet 1. PRODUCT NAME MEROPENEM RANBAXY 500 mg powder for injection MEROPENEM RANBAXY 1 g powder for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each MEROPENEM RANBAXY 500 mg

More information

Pharmacologyonline 1: (2010) ewsletter Singh and Kochbar. Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of

Pharmacologyonline 1: (2010) ewsletter Singh and Kochbar. Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of Cefoperazone Sulbactam Singh M*, Kochhar P* Medical & Research Division, Pfizer India. Summary Antimicrobial resistance is associated with

More information

ICU Volume 11 - Issue 3 - Autumn Series

ICU Volume 11 - Issue 3 - Autumn Series ICU Volume 11 - Issue 3 - Autumn 2011 - Series Impact of Pharmacokinetics of Antibiotics in ICU Clinical Practice Introduction The efficacy of a drug is mainly dependent on its ability to achieve an effective

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 October 2006

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 October 2006 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 October 2006 CUBICIN 350 mg (daptomycin), powder for perfusion solution Box of 1 bottle (CIP code: 567 219-3) CUBICIN

More information

β-lactamase inhibitors

β-lactamase inhibitors β-lactamase inhibitors Properties, microbiology & enzymology DAVID M LIVERMORE Professor of Medical Microbiology, UEA Lead on Antibiotic Resistance, Public Health England β-lactamase classes A B C D Serine

More information

PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS

PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS Dr. J. Fernández. Head of the Liver Unit Hospital Clinic Barcelona, Spain AEEH Postgraduate Course, Madrid, February 15 2017 Prevalence of

More information

Drug dosing in Extremes of Weight

Drug dosing in Extremes of Weight Drug dosing in Extremes of Weight The Plump & Heavy versus The Skinny & Light Maria Minerva P. Calimag, MD, MSc, PhD, DPBA, FPSECP PROFESSOR Departments of Pharmacology, Anesthesiology and Clinical Epidemiology

More information

Is the package insert correct? PK considerations

Is the package insert correct? PK considerations Is the package insert correct? PK considerations Jason A Roberts B Pharm (Hons), PhD, FSHP Professor of Medicine and Pharmacy The University of Queensland, Australia Royal Brisbane and Women s Hospital,

More information

Β-lactam antibiotics PENICILLINS DR. MOHAMMED NOORALDEEN AL-QATTAN

Β-lactam antibiotics PENICILLINS DR. MOHAMMED NOORALDEEN AL-QATTAN Β-lactam antibiotics PENICILLINS DR. MOHAMMED NOORALDEEN AL-QATTAN Brief history 1928: Alexander Fleming noted that growth of bacterial colonies is inhibited by co-existence of fungal colonies. Fleming

More information

Resistance to new anti-grampositive. Roland Leclercq, Microbiology, CHU Cote de Nacre, Caen, France

Resistance to new anti-grampositive. Roland Leclercq, Microbiology, CHU Cote de Nacre, Caen, France Resistance to new anti-grampositive agents Roland Leclercq, Microbiology, CHU Cote de Nacre, Caen, France Recently available antimicrobials against MDR Gram-positive infections Cyclic lipopeptide: daptomycin

More information

This letter authorises the extended use of the following guidance until 1st December 2018:

This letter authorises the extended use of the following guidance until 1st December 2018: NHS Grampian Westholme Woodend Hospital Queens Road ABERDEEN AB15 6LS NHS Grampian Date 29 1h May 2018 Our Ref FApenicillin/hype/MGPG/May 18 Enquiries to Frances Adamson Extension 56689 Direct Line 01224

More information

2. QUALITATIVE AND QUANTITATIVE COMPOSITION One sachet contains 5.631g fosfomycin trometamol equivalent to 3.0 g fosfomycin.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION One sachet contains 5.631g fosfomycin trometamol equivalent to 3.0 g fosfomycin. Doctor leaflet 1. NAME OF THE MEDICINAL PRODUCT MONUROL 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One sachet contains 5.631g fosfomycin trometamol equivalent to 3.0 g fosfomycin. Excipients: One sachet

More information

Adult Dose. Adults Day 1: 1mg/kg daily Day 2: 2mg/kg daily Day 3 onwards: 3mg/kg daily. Where appropriate consider rounding dose to nearest 50mg.

Adult Dose. Adults Day 1: 1mg/kg daily Day 2: 2mg/kg daily Day 3 onwards: 3mg/kg daily. Where appropriate consider rounding dose to nearest 50mg. AMIKACIN All ages>1month: 30mg/kg daily 1.5g once daily IV infusion over 30-60 Monitor renal function before treatment and weekly. Caution if used with other nephrotoxic drugs. Levels required. Trough

More information

Pharmacologyonline 3: (2009) ewsletter Singh et al.

Pharmacologyonline 3: (2009) ewsletter Singh et al. USE OF CEFOPERAZO E - SULBACTAM 2:1 I PATIE TS WITH COMPROMISED RE AL FU CTIO Singh M*, Kochhar P*, Suvarna V*, Patel A** * Medical & Research Division, Pfizer India. ** Infectious Diseases Clinic, "VEDANTA"

More information

Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria

Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria Infect Dis Ther (2015) 4:391 415 DOI 10.1007/s40121-015-0093-7 REVIEW Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria Phillip J. Bergen Zackery P. Bulman Cornelia B. Landersdorfer

More information

ALERT. Clinical microbiology considerations related to the emergence of. New Delhi metallo beta lactamases (NDM 1) and Klebsiella

ALERT. Clinical microbiology considerations related to the emergence of. New Delhi metallo beta lactamases (NDM 1) and Klebsiella ALERT Clinical microbiology considerations related to the emergence of New Delhi metallo beta lactamases (NDM 1) and Klebsiella pneumoniae carbapenemases (KPC) amongst hospitalized patients in South Africa

More information

PART VI. SUMMARY OF THE RISK MANAGEMENT PLAN Summary of risk management plan for ZINFORO

PART VI. SUMMARY OF THE RISK MANAGEMENT PLAN Summary of risk management plan for ZINFORO PART VI. SUMMARY OF THE RISK MANAGEMENT PLAN Summary of risk management plan for ZINFORO This is a summary of the risk management plan (RMP) for ZINFORO. The RMP details important risks of ZINFORO, how

More information

ZINEX. Composition Each tablet contains Cefuroxime (as axetil) 250 or 500 mg

ZINEX. Composition Each tablet contains Cefuroxime (as axetil) 250 or 500 mg ZINEX Composition Each tablet contains Cefuroxime (as axetil) 250 or 500 mg Tablets Action Cefuroxime axetil owes its bactericidal activity to the parent compound cefuroxime. Cefuroxime is a well-characterized

More information

DORIPENEM: THE NEWEST MEMBER OF THE CARBAPENEM FAMILY

DORIPENEM: THE NEWEST MEMBER OF THE CARBAPENEM FAMILY Volume 23, Issue 4 January 2008 DORIPENEM: THE NEWEST MEMBER OF THE CARBAPENEM FAMILY as well as for treatment of complicated urinary tract infection (cuti), including pyelonephritis. The following article

More information

Canward James A Karlowsky PhD, Mel DeCorby MSc, Daryl J Hoban PhD, George G Zhanel PhD

Canward James A Karlowsky PhD, Mel DeCorby MSc, Daryl J Hoban PhD, George G Zhanel PhD Canward 2007 In vitro activities of ceftobiprole and doripenem tested against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens isolated from patients in

More information

Below is an overview of the oral and poster presentations featuring cefiderocol and S at IDWeek 2017:

Below is an overview of the oral and poster presentations featuring cefiderocol and S at IDWeek 2017: SHIONOGI TO HIGHLIGHT RESEARCH ON CEFIDEROCOL (S-649266), A SIDEROPHORE CEPHALOSPORIN, AND S-033188, A CAP-DEPENDENT ENDONUCLEASE INHIBITOR FOR TREATMENT OF INFLUENZA, AT IDWEEK 2017 OSAKA, Japan and FLORHAM

More information

B. Incorrect! Peginterferon α-2a is used for the treatment of chronic hepatitis B and may be preferable to interferon- α.

B. Incorrect! Peginterferon α-2a is used for the treatment of chronic hepatitis B and may be preferable to interferon- α. Pharmacology - Problem Drill 24: Antibiotics, Antifungal and Antiviral Drugs Question No. 1 of 10 1. reduces the replication of influenza A and B viruses by inhibiting viral neuraminidase. Question #01

More information

New treatments of multidrug-resistant Gram-negative ventilatorassociated

New treatments of multidrug-resistant Gram-negative ventilatorassociated Review Article Page 1 of 22 New treatments of multidrug-resistant Gram-negative ventilatorassociated pneumonia Garyphallia Poulakou 1, Styliani Lagou 1, Drosos E. Karageorgopoulos 2, George Dimopoulos

More information

Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides

Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides Clin Pharmacokinet (2018) 57:797 816 https://doi.org/10.1007/s40262-017-0623-4 REVIEW ARTICLE Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides Valentin

More information

Update on CLSI and EUCAST

Update on CLSI and EUCAST Update on CLSI and EUCAST 1 Completed work» Cephalosporin breakpoints for Enterobacteriaceae ESBL screens MIC versus resistance mechanism» Carbapenem breakpoints for Enterobacteriaceae Modified Hodge Test»

More information

Back to the Future: Using Aminoglycosides Again and How to Dose Them Optimally

Back to the Future: Using Aminoglycosides Again and How to Dose Them Optimally INVITED ARTICLE ANTIMICROBIAL RESISTANCE George M. Eliopoulos, Section Editor Back to the Future: Using Aminoglycosides Again and How to Dose Them Optimally George L. Drusano, Paul G. Ambrose, Sujata M.

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A Abdominal catastrophes in ICU, 1017 1044. See also specific types, e.g., Abdominal compartment syndrome treatment of, 1032 1037 antimicrobial,

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Doribax 250 mg powder for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains doripenem monohydrate

More information

Continuous vs Intermittent Dosing of Antibiotics in Critically-Ill Patients

Continuous vs Intermittent Dosing of Antibiotics in Critically-Ill Patients Continuous vs Intermittent Dosing of Antibiotics in Critically-Ill Patients Jan O Friedrich, MD DPhil Associate Professor of Medicine, University of Toronto Medical Director, MSICU St. Michael s Hospital,

More information